Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Source: CNBC Top Stories | Published: October 26, 2025, 4:26 pm | Read Original

Neutral 0.0

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.

Read Source Login to use Pulse AI

Pulse AI Analysis

Pulse analysis not available yet. Click "Get Pulse" above.

This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.

More Like This

Glideslope AI

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.

CNBC Top Stories • Oct 26, 2025 • Found on Glideslope.ai

Post hash: m7uz0rk • glideslope.ai/post/m7uz0rk

Sentiment

Neutral • Score: 0.0

-100 (Bearish) +100 (Bullish)

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!

Pulse AI Analysis

Related Insights

More Like This

Gavin Newsom on opposing Donald Trump: "He's a wrecking ball"

Buy MSG stock because the winning New York Knicks are growing in value, Citigroup says

Kyrgyzstan launches stablecoin on BNB Chain, confirms future CBDC rollout

Rubio says commitment to Taiwan won't change amid trade talks with China

Kyrgyzstan launches stablecoin on BNB Chain, confirms future CBDC rollout

JPMorgan tries to get off hook for $115M in legal bills for cons who scammed them out of $175M